Understand the source comparison
GHRP-2 Acetate vs Other Appetite Stimulants: Mechanism and Timeline Comparison
GHRP-2 Acetate Direct GHS-R1a agonist; bypasses leptin signaling 20–40 min 60–90 min 2–4 hours Most predictable onset and dose-response curve; works independent of metabolic state; requires injection GHRP-6 GHS-R1a agonist with higher ghrelin mimicry 15–30 min
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2 Acetate
- Direct GHS-R1a agonist; bypasses leptin signaling
- 20–40 min
- 60–90 min
- 2–4 hours
- Most predictable onset and dose-response curve; works independent of metabolic state; requires injection
- GHRP-6
- GHS-R1a agonist with higher ghrelin mimicry
- 15–30 min
- 45–75 min
- 2–3 hours
- Faster onset but shorter duration; stronger acute hunger but less sustained effect; higher nausea incidence
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist; long-acting
- 60–120 min
- 3–6 hours
- 24+ hours
- Oral dosing convenience; sustained appetite elevation across the day; less controllable than injectable peptides for acute meal timing
- Megestrol Acetate
- Synthetic progestin; unclear appetite mechanism
- 2–4 weeks
- 4–8 weeks
- Weeks to months
- Slow onset; used for chronic wasting; hormonal side effects limit research applicability
- Dronabinol (THC)
- CB1 receptor agonist in hypothalamus
- 30–60 min (oral)
- 4–6 hours
- Psychoactive effects confound appetite-only research; highly variable individual response; oral bioavailability inconsistent
- GHRP-2 Acetate offers the most precise temporal control of appetite stimulation among available research compounds. Injectable administration with predictable 20–40 minute onset allows researchers to time meals exactly when ghrelin pathway activation peaks, which is critical for controlled feeding studies. The 2–4 hour duration window aligns well with single-meal protocols without creating prolonged appetite drive that complicates multi-day experiments.